Innate Pharma Falls After Modest Efficacy Signal in Post-Padcev Bladder Cancer
Innate Pharma stock slides after mixed Phase 1 readout for its Nectin-4 ADC IPH4502. Good tolerability, but efficacy signal in key bladder cancer group remains early and modest.